Renal medullary carcinoma

Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy

Edward M. Schaeffer, Thomas J. Guzzo, Kyle A. Furge, George Netto, Michael Westphal, Karl Dykema, Ximing Yang, Ming Zhou, Bin Tean Teh, Christian Pavlovich

Research output: Contribution to journalArticle

Abstract

Study Type - Aetiology (case series) Level of Evidence4 OBJECTIVE To present the molecular rationale and potential clinical benefit of topoisomerase II (TopoII)-inhibiting therapy for renal medullary carcinoma (RMC), a rare but extremely lethal form of kidney cancer that classically afflicts young men with sickle-cell trait. The current therapeutic approach with these aggressive tumours is radical nephrectomy followed by systemic chemotherapy, but the prognosis remains dismal. MATERIALS AND METHODS The whole-genome expression was analysed in four RMC tumours. We also report a case of metastatic RMC in which a complete response was achieved for 9 months using a TopoII-inhibiting therapy. RESULTS Expanded whole-genome expression analysis showed increases of TopoII in all cases. There was also overall deregulation of DNA remodelling and repair, and an ontological association between RMC and urothelial carcinoma. Using a TopoII-inhibiting agent, there was a complete response for 9 months in a patient with metastatic RMC. CONCLUSION This report provides molecular evidence for the rational use of TopoII inhibitors in the treatment of RMC.

Original languageEnglish (US)
Pages (from-to)62-65
Number of pages4
JournalBJU International
Volume106
Issue number1
DOIs
StatePublished - Jul 2010

Fingerprint

Medullary Carcinoma
Type II DNA Topoisomerase
Kidney
Therapeutics
Genome
Brain Stem Neoplasms
Sickle Cell Trait
Topoisomerase II Inhibitors
Kidney Neoplasms
Nephrectomy
DNA Repair
Carcinoma
Drug Therapy
Neoplasms

Keywords

  • Chemotherapy
  • Renal medullary carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Renal medullary carcinoma : Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. / Schaeffer, Edward M.; Guzzo, Thomas J.; Furge, Kyle A.; Netto, George; Westphal, Michael; Dykema, Karl; Yang, Ximing; Zhou, Ming; Teh, Bin Tean; Pavlovich, Christian.

In: BJU International, Vol. 106, No. 1, 07.2010, p. 62-65.

Research output: Contribution to journalArticle

Schaeffer, EM, Guzzo, TJ, Furge, KA, Netto, G, Westphal, M, Dykema, K, Yang, X, Zhou, M, Teh, BT & Pavlovich, C 2010, 'Renal medullary carcinoma: Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy', BJU International, vol. 106, no. 1, pp. 62-65. https://doi.org/10.1111/j.1464-410X.2009.09139.x
Schaeffer, Edward M. ; Guzzo, Thomas J. ; Furge, Kyle A. ; Netto, George ; Westphal, Michael ; Dykema, Karl ; Yang, Ximing ; Zhou, Ming ; Teh, Bin Tean ; Pavlovich, Christian. / Renal medullary carcinoma : Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. In: BJU International. 2010 ; Vol. 106, No. 1. pp. 62-65.
@article{0b7ea4e58bcf440183e740c5acf815f1,
title = "Renal medullary carcinoma: Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy",
abstract = "Study Type - Aetiology (case series) Level of Evidence4 OBJECTIVE To present the molecular rationale and potential clinical benefit of topoisomerase II (TopoII)-inhibiting therapy for renal medullary carcinoma (RMC), a rare but extremely lethal form of kidney cancer that classically afflicts young men with sickle-cell trait. The current therapeutic approach with these aggressive tumours is radical nephrectomy followed by systemic chemotherapy, but the prognosis remains dismal. MATERIALS AND METHODS The whole-genome expression was analysed in four RMC tumours. We also report a case of metastatic RMC in which a complete response was achieved for 9 months using a TopoII-inhibiting therapy. RESULTS Expanded whole-genome expression analysis showed increases of TopoII in all cases. There was also overall deregulation of DNA remodelling and repair, and an ontological association between RMC and urothelial carcinoma. Using a TopoII-inhibiting agent, there was a complete response for 9 months in a patient with metastatic RMC. CONCLUSION This report provides molecular evidence for the rational use of TopoII inhibitors in the treatment of RMC.",
keywords = "Chemotherapy, Renal medullary carcinoma",
author = "Schaeffer, {Edward M.} and Guzzo, {Thomas J.} and Furge, {Kyle A.} and George Netto and Michael Westphal and Karl Dykema and Ximing Yang and Ming Zhou and Teh, {Bin Tean} and Christian Pavlovich",
year = "2010",
month = "7",
doi = "10.1111/j.1464-410X.2009.09139.x",
language = "English (US)",
volume = "106",
pages = "62--65",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Renal medullary carcinoma

T2 - Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy

AU - Schaeffer, Edward M.

AU - Guzzo, Thomas J.

AU - Furge, Kyle A.

AU - Netto, George

AU - Westphal, Michael

AU - Dykema, Karl

AU - Yang, Ximing

AU - Zhou, Ming

AU - Teh, Bin Tean

AU - Pavlovich, Christian

PY - 2010/7

Y1 - 2010/7

N2 - Study Type - Aetiology (case series) Level of Evidence4 OBJECTIVE To present the molecular rationale and potential clinical benefit of topoisomerase II (TopoII)-inhibiting therapy for renal medullary carcinoma (RMC), a rare but extremely lethal form of kidney cancer that classically afflicts young men with sickle-cell trait. The current therapeutic approach with these aggressive tumours is radical nephrectomy followed by systemic chemotherapy, but the prognosis remains dismal. MATERIALS AND METHODS The whole-genome expression was analysed in four RMC tumours. We also report a case of metastatic RMC in which a complete response was achieved for 9 months using a TopoII-inhibiting therapy. RESULTS Expanded whole-genome expression analysis showed increases of TopoII in all cases. There was also overall deregulation of DNA remodelling and repair, and an ontological association between RMC and urothelial carcinoma. Using a TopoII-inhibiting agent, there was a complete response for 9 months in a patient with metastatic RMC. CONCLUSION This report provides molecular evidence for the rational use of TopoII inhibitors in the treatment of RMC.

AB - Study Type - Aetiology (case series) Level of Evidence4 OBJECTIVE To present the molecular rationale and potential clinical benefit of topoisomerase II (TopoII)-inhibiting therapy for renal medullary carcinoma (RMC), a rare but extremely lethal form of kidney cancer that classically afflicts young men with sickle-cell trait. The current therapeutic approach with these aggressive tumours is radical nephrectomy followed by systemic chemotherapy, but the prognosis remains dismal. MATERIALS AND METHODS The whole-genome expression was analysed in four RMC tumours. We also report a case of metastatic RMC in which a complete response was achieved for 9 months using a TopoII-inhibiting therapy. RESULTS Expanded whole-genome expression analysis showed increases of TopoII in all cases. There was also overall deregulation of DNA remodelling and repair, and an ontological association between RMC and urothelial carcinoma. Using a TopoII-inhibiting agent, there was a complete response for 9 months in a patient with metastatic RMC. CONCLUSION This report provides molecular evidence for the rational use of TopoII inhibitors in the treatment of RMC.

KW - Chemotherapy

KW - Renal medullary carcinoma

UR - http://www.scopus.com/inward/record.url?scp=77953206989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953206989&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2009.09139.x

DO - 10.1111/j.1464-410X.2009.09139.x

M3 - Article

VL - 106

SP - 62

EP - 65

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -